HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

This study has been terminated.
Information provided by:
Cubist Pharmaceuticals LLC
ClinicalTrials.gov Identifier:
First received: September 27, 2005
Last updated: February 12, 2007
Last verified: February 2007
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether or not the drugs prevent the Hepatitis B virus from infecting the new liver.

Condition Intervention Phase
Hepatitis B
Liver Transplantation
Drug: HepeX-B
Drug: Hepatitis B Immune Globulin (HBIg)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-Bä, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients Who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis B Virus Infection

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals LLC:

Estimated Study Completion Date: August 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients who are 18 years of age or older,
  • Patients who are at least 6 months post first orthotopic liver transplantation (living or cadaveric donor) for treatment of end-stage liver disease due to HBV infection,
  • Patients who have received HBIg since transplantation and are on a stable regimen (i.e., same dose and frequency) for at least the 3 months immediately preceding study entry (Day 1),
  • Patients who have received treatment with an inhibitor of HBV polymerase for at least the 3 months immediately preceding study entry (Day 1),
  • Patients with undetectable HBsAg and HBV DNA concentrations on two consecutive tests at least 1 week apart during the screening period,
  • Female patients who are of childbearing potential, and males whose partners are women of childbearing potential, are required to use adequate contraception, and
  • Patients who are able to provide written informed consent.
  • Patients who successfully complete the initial 20-week treatment in the core trial are eligible for the 52-week extension phase.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding,
  • Patients who have received another organ transplant that requires immunosuppression,
  • Patients who are co-infected with hepatitis delta virus (HDV), hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV),
  • Patients with clinical conditions or diseases, which, in the judgment of the investigator, would place the patient at undue risk, interfere with study participation, or confound the results of the study, and/or
  • Patients who have participated in clinical studies in the 3 months prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00228592

United States, California
Los Angeles, California, United States
California Pacific Medical Center
San Francisco, California, United States
San Francisco, California, United States
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States
United States, Nebraska
University of Nebraska
Omaha, Nebraska, United States
United States, New York
Mt. Sinai
New York, New York, United States
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
United States, Pennsylvania
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States
Metropolitan Liver Diseases/Gastroenterology Center
Fairfax, Virginia, United States
Virginia Commonwealth University Health System
Richmond, Virginia, United States
Centre Hepato-Biliaire Hospital Paul Brousse
Paris, France
Humbolt University Virchow Clinic Dept. Viceral and Transplant Surgery
Berlin, Germany
Hadassah University Hospital
Jerusalem, Israel
Rabin Medical Center
Petach Tikva, Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
New Zealand
Auckland City Hospital
Auckland, New Zealand
Hospital La Fe Servicio de Medicina Degestiva
Valencia, Spain
United Kingdom
Royal Free Hospital
London, United Kingdom
Sponsors and Collaborators
Cubist Pharmaceuticals LLC
Principal Investigator: Vinod Rustgi, MD Metropolitan Liver Diseases/ Gastroenterology Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00228592     History of Changes
Other Study ID Numbers: HepeX-B 2003-12 
Study First Received: September 27, 2005
Last Updated: February 12, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
End Stage Liver Disease
Hepatitis A
Hepatitis B
Liver Diseases
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Hepatic Insufficiency
Hepatitis, Viral, Human
Liver Failure
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 11, 2016